IGF-1 LR3 vs IGF1 LR3 — Same Peptide, Different Names
The confusion around what's the difference between IGF-1 LR3 and IGF1 LR3 comes from notation inconsistency across suppliers, publications, and research databases. Not from any actual structural or functional difference. Both terms describe the exact same 83-amino-acid peptide: Long R3 Insulin-Like Growth Factor-1. The hyphen in 'IGF-1' versus the absence of a hyphen in 'IGF1' is a stylistic choice, not a biochemical distinction. Some manufacturers hyphenate the abbreviation, others don't. The peptide itself remains unchanged.
We've worked with research-grade peptides for years, and this naming discrepancy creates more confusion than it should. The important part isn't the hyphen. It's understanding what 'LR3' means and why that modification matters for experimental protocols.
What's the difference between IGF-1 LR3 and IGF1 LR3?
There is no difference between IGF-1 LR3 and IGF1 LR3. They are the same peptide. Both names refer to Long R3 Insulin-Like Growth Factor-1, a synthetic analogue of natural IGF-1 with an extended half-life (20–30 hours versus 10–12 minutes for native IGF-1) due to structural modifications at the N-terminus. The hyphen is a notational preference, not a functional distinction. Suppliers and researchers use both forms interchangeably.
The reason both names exist is straightforward: scientific naming conventions allow flexibility in abbreviation formatting. 'IGF-1' follows hyphenated nomenclature standard in endocrinology literature, while 'IGF1' reflects condensed notation common in peptide synthesis and commercial catalogs. Neither is wrong. Both point to the same compound: a recombinant peptide engineered to resist degradation by IGF-binding proteins (IGFBPs) and maintain prolonged activity in biological systems.
This article covers what the 'LR3' modification actually does, why the extended half-life matters for research applications, how IGF-1 LR3 differs from native IGF-1, and what researchers should verify when sourcing this peptide regardless of how the supplier writes the name.
What 'LR3' Actually Means (And Why It Matters)
LR3 stands for Long R3. A designation that describes two specific structural modifications to the native IGF-1 peptide sequence. First, the peptide includes a 13-amino-acid N-terminal extension. Second, the glutamic acid residue at position 3 in native IGF-1 is replaced with arginine (R). These changes fundamentally alter how the peptide behaves in biological systems.
Native IGF-1 has a half-life of 10–12 minutes because it binds tightly to IGF-binding proteins (IGFBPs), which sequester it and prevent receptor activation. The LR3 modifications reduce IGFBP binding affinity by approximately 100-fold. That means IGF-1 LR3 circulates longer, maintains higher free concentrations, and activates IGF-1 receptors more consistently than the endogenous form.
The extended half-life. 20 to 30 hours depending on storage and reconstitution conditions. Allows researchers to dose less frequently while maintaining stable peptide levels across experimental timelines. This is why IGF-1 LR3 is preferentially used in cell culture models and tissue studies where sustained receptor activation matters more than transient signaling spikes.
Our team has seen researchers struggle with dosing schedules because they didn't realize the LR3 form was structurally different from recombinant human IGF-1 (rhIGF-1). The half-life difference isn't subtle. It's a 150× extension. That changes everything about protocol design.
How IGF-1 LR3 Differs from Native IGF-1
Beyond the half-life, IGF-1 LR3 exhibits measurably different receptor binding dynamics. Native IGF-1 activates both IGF-1 receptors (IGF1R) and insulin receptors (IR) with relatively balanced affinity. IGF-1 LR3 retains high IGF1R affinity but shows reduced insulin receptor cross-reactivity. This selectivity matters in metabolic research where isolating IGF1R-mediated effects from insulin-like effects is critical.
The N-terminal extension also impacts peptide stability during storage and handling. Native IGF-1 degrades rapidly at room temperature and loses potency within hours if not refrigerated immediately after reconstitution. IGF-1 LR3 tolerates brief temperature excursions better. Though long-term storage still requires −20°C for lyophilized powder and 2–8°C for reconstituted solutions.
One functional consequence researchers often miss: IGF-1 LR3's reduced IGFBP binding means it doesn't rely on carrier proteins for distribution. Native IGF-1 circulates almost entirely bound to IGFBP-3 and the acid-labile subunit (ALS) in vivo. IGF-1 LR3 circulates as free peptide. That makes it more bioavailable in simplified experimental systems like serum-free cell culture, but also means it clears faster in whole-organism models where IGFBPs would normally extend circulation time paradoxically through sequestration-release dynamics.
The short version: if your research question involves sustained IGF1R activation without the confounding effects of binding proteins, IGF-1 LR3 is the tool. If you're studying physiological IGF-1 signaling as it occurs naturally. Complete with IGFBP regulation. Native IGF-1 is the appropriate control.
What's the Difference Between IGF-1 LR3 and IGF1 LR3: Notation Comparison
| Notation | Full Name | Amino Acid Length | Half-Life | Primary Use Case | IGFBP Binding Affinity | Bottom Line |
|---|---|---|---|---|---|---|
| IGF-1 LR3 | Long R3 Insulin-Like Growth Factor-1 | 83 amino acids | 20–30 hours | Sustained receptor activation in vitro | ~100× lower than native IGF-1 | Hyphenated notation. Same peptide as IGF1 LR3 |
| IGF1 LR3 | Long R3 Insulin-Like Growth Factor-1 | 83 amino acids | 20–30 hours | Sustained receptor activation in vitro | ~100× lower than native IGF-1 | Non-hyphenated notation. Same peptide as IGF-1 LR3 |
| Native IGF-1 | Insulin-Like Growth Factor-1 | 70 amino acids | 10–12 minutes | Physiological signaling studies | High (normal IGFBP-3 binding) | Endogenous form. Structurally distinct from LR3 variants |
| rhIGF-1 | Recombinant Human IGF-1 | 70 amino acids | 10–12 minutes | Replacement therapy models | High (normal IGFBP-3 binding) | Identical to native IGF-1, produced via recombinant synthesis |
Key Takeaways
- IGF-1 LR3 and IGF1 LR3 are identical. The hyphen is a notational preference, not a functional difference.
- The 'LR3' modification adds 13 amino acids at the N-terminus and substitutes arginine for glutamic acid at position 3, reducing IGFBP binding by approximately 100-fold.
- IGF-1 LR3 has a half-life of 20–30 hours compared to 10–12 minutes for native IGF-1, enabling sustained receptor activation with less frequent dosing.
- Reduced IGFBP binding makes IGF-1 LR3 more bioavailable in serum-free conditions but less representative of physiological IGF-1 dynamics in whole-organism models.
- When sourcing this peptide, verify purity via HPLC certificate of analysis (COA) and confirm amino acid sequencing matches the 83-residue LR3 structure. Notation inconsistency across suppliers is common, but the peptide sequence should be uniform.
What If: IGF-1 LR3 Scenarios
What If a Supplier Lists Both IGF-1 LR3 and IGF1 LR3 as Separate Products?
Request the certificate of analysis (COA) and amino acid sequence for both listings. If the sequences are identical and both show 83 amino acids with the Long R3 modification, they're the same product listed twice under different notations. Some suppliers duplicate catalog entries to capture search traffic for both naming conventions. If the sequences differ. Or one is 70 amino acids instead of 83. One listing is native IGF-1, not the LR3 variant. Always verify peptide length and modification status before ordering.
What If My Protocol Specifies 'IGF-1 LR3' but I Can Only Source 'IGF1 LR3'?
Use the peptide you sourced. The hyphen doesn't change the structure, function, or experimental outcome. Cross-check the molecular weight (9117.5 Da for IGF-1 LR3) and sequence on the supplier's COA against published references. If those match, the notation difference is irrelevant. Document the supplier and lot number in your methods section so results can be replicated regardless of how future suppliers format the name.
What If I'm Comparing Data from Studies That Use Different Notations?
Confirm that all studies used the 83-amino-acid Long R3 variant, not native 70-amino-acid IGF-1. The easiest check is half-life: if the study reports sustained activity beyond 12 hours without re-dosing, it's almost certainly LR3. If activity drops off within 30–60 minutes, it's native IGF-1. Notation inconsistency across literature is common, but the peptide's biological behavior. Especially half-life and IGFBP independence. Will reveal which form was actually used.
The Blunt Truth About IGF-1 LR3 Naming Confusion
Here's the honest answer: the 'difference' between IGF-1 LR3 and IGF1 LR3 is a non-issue that wastes more research time than it should. Suppliers create the confusion by listing the same peptide under multiple names to improve search visibility. Researchers perpetuate it by not checking certificates of analysis before ordering. The peptide is identical. The hyphen doesn't matter. What does matter is verifying you're getting the Long R3 variant. Not native IGF-1 mislabeled as LR3, and not a shorter analogue with partial modifications.
If a supplier can't provide an HPLC trace showing 83 amino acids and a molecular weight of 9117.5 Da, don't order from them. The notation they use is irrelevant if the peptide inside the vial isn't correctly synthesized. We've seen too many protocols fail because researchers assumed 'IGF-1 LR3' on a label guaranteed the right compound. It doesn't. The COA guarantees it. Everything else is marketing.
Why Peptide Sourcing Matters More Than Notation
The real research risk isn't confusing IGF-1 LR3 with IGF1 LR3. It's receiving a peptide that's mislabeled, under-dosed, or contaminated with synthesis byproducts. Small-batch peptide synthesis introduces variability that hyphenation choices don't. A 2019 analysis of commercially available research peptides found that 22% of samples tested below the stated purity threshold, and 8% contained incorrect sequences entirely.
When evaluating suppliers, prioritize these verification points over notation style: HPLC purity ≥95%, mass spectrometry confirmation of molecular weight, amino acid analysis confirming sequence accuracy, endotoxin testing for cell culture applications, and transparent lot-specific COAs available before purchase. Real Peptides publishes third-party testing results for every batch we synthesize. Because the difference between a successful experiment and a failed one isn't the hyphen in the product name, it's the purity of what you're actually injecting into your model.
If you're building a protocol around sustained IGF1R activation, the peptide's half-life and IGFBP resistance are what matter. Whether the supplier writes it as IGF-1 LR3 or IGF1 LR3 is irrelevant if the peptide performs as expected. But if the peptide degrades in 20 minutes instead of 20 hours because it was actually native IGF-1 mislabeled as LR3, your entire dataset is invalid. Verify the structure first. Ignore the hyphen.
The most common sourcing mistake isn't ordering the wrong notation. It's failing to confirm the peptide matches its advertised specifications before use. A COA that lists 83 amino acids, a molecular weight of 9117.5 Da, and HPLC purity above 95% tells you everything you need. The product name tells you almost nothing.
Frequently Asked Questions
Is there any functional difference between IGF-1 LR3 and IGF1 LR3?▼
No. IGF-1 LR3 and IGF1 LR3 are the same peptide — the hyphen is a notational preference used inconsistently across suppliers and research literature. Both refer to Long R3 Insulin-Like Growth Factor-1, an 83-amino-acid synthetic analogue with reduced IGFBP binding and an extended half-life of 20–30 hours. The peptide’s structure, function, and experimental behavior are identical regardless of hyphenation.
Why do some suppliers list both IGF-1 LR3 and IGF1 LR3 separately?▼
Suppliers duplicate catalog listings to capture search traffic for both naming conventions. Researchers search using both ‘IGF-1 LR3’ and ‘IGF1 LR3’, so listing the same peptide twice increases visibility. This is a marketing tactic, not an indication of different products. Always request the certificate of analysis (COA) to confirm the peptide sequence and molecular weight match the Long R3 variant (83 amino acids, 9117.5 Da).
How can I verify I’m receiving genuine IGF-1 LR3 regardless of notation?▼
Check the supplier’s certificate of analysis (COA) for three critical specifications: amino acid length (must be 83, not 70), molecular weight (must be 9117.5 Da), and HPLC purity (should be ≥95%). If the COA lists 70 amino acids or a molecular weight around 7649 Da, you’re receiving native IGF-1, not the LR3 variant. The product name is irrelevant — the COA is the only reliable verification.
What does the ‘LR3’ modification do to IGF-1?▼
LR3 refers to two structural changes: a 13-amino-acid N-terminal extension and an arginine substitution at position 3 (replacing glutamic acid). These modifications reduce binding affinity to IGF-binding proteins (IGFBPs) by approximately 100-fold, extending the peptide’s half-life from 10–12 minutes (native IGF-1) to 20–30 hours (IGF-1 LR3). The result is sustained receptor activation without frequent re-dosing, making it preferable for in vitro research requiring stable IGF1R signaling over extended periods.
Can I use IGF-1 LR3 and native IGF-1 interchangeably in experiments?▼
No. IGF-1 LR3 and native IGF-1 exhibit fundamentally different pharmacokinetics and receptor dynamics. Native IGF-1 has a 10–12 minute half-life and binds tightly to IGFBPs, making it appropriate for physiological signaling studies. IGF-1 LR3 resists IGFBP binding and maintains activity for 20–30 hours, making it suitable for sustained receptor activation models. Using one in place of the other will produce different experimental outcomes.
Why does IGF-1 LR3 have a longer half-life than native IGF-1?▼
The half-life extension results from reduced binding to IGF-binding proteins (IGFBPs). Native IGF-1 binds tightly to IGFBP-3 and is rapidly sequestered, limiting free peptide availability and shortening its active duration to 10–12 minutes. The LR3 modification reduces IGFBP affinity by approximately 100-fold, allowing the peptide to circulate as free, bioavailable IGF-1 for 20–30 hours. This makes dosing less frequent and receptor activation more sustained.
What purity level should I expect for research-grade IGF-1 LR3?▼
Research-grade IGF-1 LR3 should have an HPLC purity of ≥95%. Lower purity levels indicate synthesis byproducts, incomplete sequences, or contaminants that can interfere with experimental results. Suppliers offering peptides below 90% purity are not suitable for reproducible research. Always request a lot-specific certificate of analysis (COA) showing HPLC trace, molecular weight confirmation via mass spectrometry, and endotoxin testing if the peptide will be used in cell culture.
How should IGF-1 LR3 be stored to maintain stability?▼
Store lyophilized (powder) IGF-1 LR3 at −20°C in a sealed container with desiccant to prevent moisture absorption. Once reconstituted with sterile water or bacteriostatic water, store the solution at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles, which denature the peptide structure. Temperature excursions above 8°C for reconstituted peptide cause irreversible loss of bioactivity.
Is IGF-1 LR3 approved for human use or clinical applications?▼
No. IGF-1 LR3 is not FDA-approved for human use and is sold exclusively as a research reagent for in vitro and preclinical studies. It is not intended for therapeutic administration, athletic performance enhancement, or any clinical application. Researchers using IGF-1 LR3 must comply with institutional biosafety protocols and ensure all experimental use aligns with approved research guidelines.
What is the molecular weight of IGF-1 LR3?▼
The molecular weight of IGF-1 LR3 is 9117.5 Da. This is measurably higher than native IGF-1 (7649 Da) due to the 13-amino-acid N-terminal extension. Suppliers should confirm this molecular weight via mass spectrometry in their certificate of analysis (COA). If the listed molecular weight is closer to 7649 Da, the peptide is native IGF-1, not the LR3 variant.
